These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35967599)

  • 1. A lasting crisis affects R&D decisions of smaller firms: the Greek experience.
    Giotopoulos I; Kritikos AS; Tsakanikas A
    J Technol Transf; 2022 Aug; ():1-15. PubMed ID: 35967599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender diversity in European firms and the R&D-innovation-productivity nexus.
    Capozza C; Divella M
    J Technol Transf; 2023 Apr; ():1-22. PubMed ID: 37359815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competition and firm recovery post-COVID-19.
    Bruhn M; Demirguc-Kunt A; Singer D
    Small Bus Econ (Dordr); 2023 May; ():1-32. PubMed ID: 38625181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How innovation and ownership concentration affect the financial sustainability of energy enterprises: evidence from a transition economy.
    Duong KD; Huynh TN; Nguyen DV; Le HTP
    Heliyon; 2022 Sep; 8(9):e10474. PubMed ID: 36097476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Window of Opportunity: Radical Versus Repurposing Innovation Under Conditions of Environmental Uncertainty and Crisis.
    Dunlap DR; Santos RS; Latham SF
    IEEE Trans Eng Manag; 2024; 71():6540-6552. PubMed ID: 38665304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Productivity and firm exit during the COVID-19 crisis: cross-country evidence.
    Muzi S; Jolevski F; Ueda K; Viganola D
    Small Bus Econ (Dordr); 2023; 60(4):1719-1760. PubMed ID: 38625239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEO Overconfidence, Corporate Governance, and R&D Smoothing in Technology-Based Entrepreneurial Firms.
    Huang Y; Wang X; Li Y; Yu X
    Front Psychol; 2022; 13():944117. PubMed ID: 35910989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can R&D investment reduce the impact of COVID-19 on firm performance?-Evidence from India.
    Biswas S
    J Public Aff; 2021 Oct; ():e2773. PubMed ID: 34899063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can rising labor costs boost private sector R&D investment? : Evidence from a survey of Chinese private firms.
    Deng C; Liu Y; Gu D
    PLoS One; 2022; 17(8):e0268287. PubMed ID: 35925924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of analyst attention on the firms' innovation paths from a life cycle perspective: Evidence from China.
    Yao J; Wang D
    Heliyon; 2023 Aug; 9(8):e18940. PubMed ID: 37636392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Environmental regulation and green innovation of polluting firms in China.
    He L; Wang M
    PLoS One; 2023; 18(3):e0281303. PubMed ID: 36893093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The U-shaped impact of export quality on firms' innovation output: Empirical evidence from China.
    Cai Y; Wu G
    PLoS One; 2024; 19(2):e0298358. PubMed ID: 38394251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyzing the impact of COVID-19 on environmental innovations in manufacturing firms.
    Hermundsdottir F; Haneberg DH; Aspelund A
    Technol Soc; 2022 Feb; 68():101918. PubMed ID: 35132287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.
    Billette de Villemeur E; Versaevel B
    J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turning inward in difficulties: R&D human resource slack, technological diversification, and independent innovation.
    Li H; Zhao Y; Li Y; Wang Y
    PLoS One; 2024; 19(6):e0298453. PubMed ID: 38870238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of product subsidies on R&D investment for new energy vehicle firms: Considering quality preference of the early adopter group.
    Meng W; Wang Y; Li Y; Huang B
    PLoS One; 2020; 15(7):e0236626. PubMed ID: 32735570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental regulation, digital finance, and technological innovation: evidence from listed firms in China.
    Yang Y; Li X
    Environ Sci Pollut Res Int; 2023 Mar; 30(15):44625-44639. PubMed ID: 36696056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financing Constraints and Firm's Productivity Under the COVID-19 Epidemic Shock: Evidence of A-Shared Chinese Companies.
    Wong Z; Chen A; Taghizadeh-Hesary F; Li R; Kong Q
    Eur J Dev Res; 2023; 35(1):167-195. PubMed ID: 35194343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach.
    Hu Y; Chen S; Qiu F; Chen P; Chen S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.